Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study

BACKGROUND/AIMS: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibi, Toshifumi, Motoya, Satoshi, Ashida, Toshifumi, Sai, Souken, Sameshima, Yukinori, Nakamura, Shiro, Maemoto, Atsuo, Nii, Masahiro, Sullivan, Barbara A, Gasser Jr, Robert A., Suzuki, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667363/
https://www.ncbi.nlm.nih.gov/pubmed/30739435
http://dx.doi.org/10.5217/ir.2018.00141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667363/
https://www.ncbi.nlm.nih.gov/pubmed/30739435
http://dx.doi.org/10.5217/ir.2018.00141

Ejemplares similares